{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:35:15Z","timestamp":1761824115157,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5063-5","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T10:18:11Z","timestamp":1542363491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety profile of trifluridine\/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5947-8733","authenticated-orcid":false,"given":"Stefan","family":"Kasper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kisro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Schulz-Abelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinolf","family":"Karthaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad-Reza","family":"Rafiyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"5063_CR1","unstructured":"Robert Koch-Institut und Zentrum f\u00fcr Krebsregisterdaten. Bericht zum Krebsgeschehen in Deutschland 2016; 2016. Available at: \n                    https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebsgeschehen\/Krebsgeschehen_node.html\n                    \n                  . Accessed 25 July 2017."},{"key":"5063_CR2","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609\u201318.","journal-title":"N Engl J Med"},{"issue":"5 Suppl","key":"5063_CR3","first-page":"Abstract LBA3","volume":"32","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz H-J, Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD. Cancer and Leukemia Group B (Alliance), SWOG, and ECOG (2014) CALGB\/SWOG 80405: Phase III trial of irinotecan\/5-FU\/leucovorin (FOLFIRI) or oxaliplatin\/5-FU\/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2017;32(5 Suppl):Abstract LBA3.","journal-title":"J Clin Oncol"},{"key":"5063_CR4","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, D\u00edaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirz\u00e9n F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013\u20139.","journal-title":"J Clin Oncol."},{"key":"5063_CR5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","volume":"27","author":"K Yamazaki","year":"2016","unstructured":"Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016;27:1539\u201346.","journal-title":"Ann Oncol"},{"key":"5063_CR6","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pint\u00e9r T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Engl J Med. 2009;360:1408\u201317.","journal-title":"New Engl J Med"},{"key":"5063_CR7","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Koc\u00e1kova I, Ruff P, B\u0142asi\u0144ska-Morawiec M, \u0160makal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697\u2013705.","journal-title":"J Clin Oncol"},{"key":"5063_CR8","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"HV von Weikersthal LF","year":"2014","unstructured":"von Weikersthal LF HV, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenm\u00fcller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, M\u00fcller S, Link H, Niederle N, Rost A, H\u00f6ffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065\u201375.","journal-title":"Lancet Oncol"},{"key":"5063_CR9","unstructured":"Leitlinienprogramm Onkologie 2014. S3-Leitlinie Kolorektales Karzinom, Langversion 1.1. Available at: \n                    https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/021-007OLl_S3_KRK_2017-12_1.pdf\n                    \n                  . Accessed 14 Nov 2018."},{"key":"5063_CR10","unstructured":"Deutsche Gesellschaft f\u00fcr H\u00e4matologie und medizinische Onkologie e.V. 2016a. Kolonkarzinom - Leitlinie - Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h\u00e4matologischer und onkologischer Erkrankungen. Available at: \n                    https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/kolonkarzinom\/@@view\/html\/index.html\n                    \n                  . Accessed 25 July 2017."},{"key":"5063_CR11","unstructured":"Deutsche Gesellschaft f\u00fcr H\u00e4matologie und medizinische Onkologie e.V. 2016b. Rektumkarzinom - Leitlinie - Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h\u00e4matologischer und onkologischer Erkrankungen. Available at: \n                    https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/rektumkarzinom\/@@view\/html\/index.html\n                    \n                  . Accessed 14 Nov 2018."},{"key":"5063_CR12","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, K\u00f6hne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, \u00d6sterlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Ta\u00efeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A. Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386\u2013422.","journal-title":"Ann Oncol"},{"key":"5063_CR13","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2014.0099","volume":"12","author":"AB Benson 3rd","year":"2014","unstructured":"Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA, National Comprehensive Cancer Network. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014;12:1028\u201359.","journal-title":"J Natl Compr Canc Netw"},{"key":"5063_CR14","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"R Mayer","year":"2015","unstructured":"Mayer R, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A, RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909\u201319.","journal-title":"N Engl J Med"},{"key":"5063_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1349-7006.2007.00477.x","volume":"98","author":"OH Temmink","year":"2007","unstructured":"Temmink OH, Emura T, de Bruin M, et al. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci. 2007;98:779\u201389.","journal-title":"Cancer Sci"},{"key":"5063_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"17","author":"D DuBois","year":"1916","unstructured":"DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med. 1916;17:863\u201371.","journal-title":"Arch Int Med"},{"key":"5063_CR17","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/j.clcc.2016.04.004","volume":"15","author":"T Yoshino","year":"2016","unstructured":"Yoshino T, Uetake H, Fujita N, Furuta T, Katori J, Hara N, Muro K. TAS-102 safety in metastatic colorectal cancer: results from the first postmarketing surveillance study. Clin Colorectal Cancer. 2016;15:e205\u201311.","journal-title":"Clin Colorectal Cancer."},{"key":"5063_CR18","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1200\/JCO.2017.35.15_suppl.3559","volume":"35","author":"RJ Mayer","year":"2017","unstructured":"Mayer RJ, Grothey A, Hochster HS, Cohen S, Vukovic VM, Makris L. An open-label expanded-access study of Trifluridine \/ Tipiracil for metastatic colorectal Cancer. J Clin Oncol. 2017;35:3559.","journal-title":"J Clin Oncol"},{"key":"5063_CR19","doi-asserted-by":"publisher","first-page":"e15019","DOI":"10.1200\/JCO.2017.35.15_suppl.e15019","volume":"35","author":"PG Alfonso","year":"2017","unstructured":"Alfonso PG, Carbonero RG, Carrato A, Vieitez JM. Gravalos5 C, Pericay C, Benavides M, Delgado M, Arguilles G, Ruiz a. compassionate use program with FTD\/TPI (TAS-102) in pretreated metastatic colorectal cancer patients: Spanish real world data. J Clin Oncol. 2017;35:e15019.","journal-title":"J Clin Oncol"},{"key":"5063_CR20","doi-asserted-by":"publisher","first-page":"e000229","DOI":"10.1136\/esmoopen-2017-000229","volume":"2","author":"V Sforza","year":"2017","unstructured":"Sforza V, Martinelli E, Cardone C, Martini G, Napolitano S, Vitiello PP, Vitale P, Zanaletti N, Reginelli A, Bisceglie MD, Latiano TP, Bochicchio AM, Cecere F, Selvaggi F, Ciardiello F, Troiani T. Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine\/tipiracil (TAS-102): a single Italian institution compassionate use programme. ESMO Open. 2017;2:e000229.","journal-title":"ESMO Open"},{"issue":"3","key":"5063_CR21","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s10147-017-1220-0","volume":"23","author":"JJM Kwakman","year":"2017","unstructured":"Kwakman JJM, Vink G, Vestjens JH, Beerepoot LV, de Groot JW, Jansen RL, Opdam FL, Boot H, Creemers GJ, van Rooijen JM, Los M, Vulink AJE, Schut H, van Meerten E, Baars A, Hamberg P, Kapiteijn E, Sommeijer DW, Punt CJA, Koopman M. Feasibility and effectiveness of trifluridine\/tipiracil in metastatic colorectal cancer: real-life data from the Netherlands. Int J Clin Oncol. 2017;23(3):482\u20139 [Epub ahead of print].","journal-title":"Int J Clin Oncol"},{"key":"5063_CR22","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/j.clcc.2015.11.005","volume":"15","author":"D Kotani","year":"2016","unstructured":"Kotani D, Shitara K, Kawazoe A, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T. Safety and efficacy of FTD\/TPI monotherapy in clinical practice for patients with metastatic colorectal Cancer: experience at a single institution. Clin Colorectal Cancer. 2016;15:e109\u201315.","journal-title":"Clin Colorectal Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5063-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T19:11:14Z","timestamp":1573845074000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5063-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5063"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5063-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"assertion":[{"value":"17 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"According to the regulations of the German Medicinal Product Act (AMG \u00a721 subsection 2 no. 6), there was no need for an ethics approval in regard to the compassionate-use-program (CUP) for FTD\/TPI (Lonsurf\u00ae). Therefore, this program was not submitted to the ethics committee but reported to the German Federal Institute for Drugs and Medical Devices (BfArM). Patients were informed by the investigators about the CUP and had to sign an informed consent form (ICF) before beeing enclosed into the program. The ICF will be made available from the correponding author upon request.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The informed consent form from Servier Deutschland GmbH contained a text passage \u201cConfirmation of Use of Personal Medical Records and Personal Information\u201d and each mCRC patient of the CUP for FTD\/TPI (Lonsurf\u00ae) agreed to the processing of pseudonymized personal data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SK received authorship remuneration from SERVIER Deutschland GmbH (Germany). All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1124"}}